What are BTK inhibitor drugs?

BTK inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting BTK). 1 are currently marketed, with 20 more in clinical development.

What are the marketed BTK inhibitor drugs?

Marketed BTK inhibitor drugs include (G) BQ-L14.

BTK inhibitor

1 marketed 6 in Phase 3 8 in Phase 2 6 in Phase 1

This page covers all BTK inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting BTK, BTK (Bruton's tyrosine kinase).

Targets

BTK · BTK (Bruton's tyrosine kinase)

Marketed (1)

(G) BQ-L14 · National Taiwan University Hospital · Oncology
BQ-L14 is a small molecule that acts as a selective and potent inhibitor of the Bruton's tyrosine kinase (BTK).

Phase 3 pipeline (6)

Acalabrutinib (ACP-196) · Acerta Pharma BV · Oncology
Acalabrutinib is a selective inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell proliferation and survival signaling.
Orelabrutinib and R-CHOP · Beijing InnoCare Pharma Tech Co., Ltd. · Oncology
Orelabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks the activity of BTK, a protein involved in the activation of B cells.
PCI-32765 (Ibrutinib) · Janssen Research & Development, LLC · Oncology
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell receptor signaling and reduces proliferation of malignant B cells.
V0034CR01B · Pierre Fabre Medicament · Oncology
This drug is a selective inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
FFI-1010 · Fuji Yakuhin Co., Ltd. · Oncology
FFI-1010 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
Next-line ibrutinib · Pharmacyclics LLC. · Oncology
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, leading to reduced proliferation and survival of malignant B cells.

Phase 2 pipeline (8)

AUR101 · Aurigene Discovery Technologies Limited · Oncology
AUR101 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
LOXO-305 · Eli Lilly and Company · Oncology
Selective Bruton's tyrosine kinase (BTK) inhibitor
Acalabrutinib combination with Rituximab · AstraZeneca · Oncology
BTK inhibitor
ACP-196 · Acerta Pharma BV · Oncology
BTK inhibitor
GZ402665 · Genzyme, a Sanofi Company · Oncology
GZ402665 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
GSK1292263 · GlaxoSmithKline · Oncology
GSK1292263 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
CE-224,535 · Pfizer · Oncology
CE-224,535 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
ABBV-668 · AbbVie · Oncology
ABBV-668 is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK).

Phase 1 pipeline (6)

Acalabrutinib Treatment D · AstraZeneca · Oncology
BTK inhibitor
Acalabrutinib Treatment A · AstraZeneca · Oncology
BTK inhibitor
Acalabrutinib in combination with BR · Acerta Pharma BV · Oncology
BTK inhibitor
Acalabrutinib Treatment C · AstraZeneca · Oncology
BTK inhibitor
Acalabrutinib in combination with VR · Acerta Pharma BV · Oncology
BTK inhibitor
ABBV-453 · AbbVie · Oncology
BTK inhibitor